It’s long past time for us to say no more to the science deniers.
It’s time for us to stand up to Washington bureaucrats who think you’re not smart enough to make your own decisions. It’s time for us to stand up to people who write columns ignoring 100 years of immunity science just to score cheap and incorrect political points.
These petty tyrants in government and their enablers in the media always think they know best. They deal in the currency of fear, hoping to scare the American people into submission.
For months, I’ve heard your pleas for a return to normalcy, and for months I’ve raised the alarm loudly, publicly, and armed with studies that Dr. Anthony Fauci and the media have mostly chosen to ignore studies showing that we can in fact safely send our kids back to school and reopen the economy.
Share this article
Share this article
SAN DIEGO, May 27, 2021 /PRNewswire/ Synbal, Inc., a privately held biotechnology company specializing in the development of genetically complex, humanized mouse models for research announced today that they have received a SBIR grant from the National Institute of Allergy and Infectious Diseases to develop a novel, humanized mouse model for Covid-19 therapeutics research. Synbal is partnering with La Jolla Institute for Immunology (LJI) to fully characterize the model that will then be made available in early 2022 to the research community to accelerate the development of new therapeutics that can be used to treat this devastating pandemic.
An article written by Dr. Tamara Bhadari, a senior science writer from the Washington University School of Medicine in St. Louis, recently published an article explaining that even a mild COVID-19 infection induces lasting antibody protection that can last a lifetime. She sites a study recently published from researchers at Washington University School of Medicine […]
Human T cells can target more than 1,400 sites on SARS-CoV-2 virus
In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world. The results are striking: human T cells can target more than 1,400 sites on the SARS-CoV-2 virus. Our lab and many others have shown this very broad and diverse T cell response, says LJI Research Assistant Professor Daniela Weiskopf, Ph.D., co-author of the
Cell Host & Microbe review.
This kind of research review, called a meta-analysis, pools the results of multiple studies, and the researchers give close consideration to how the studies were conducted.
Credit: CDC
LA JOLLA In a new paper, scientists from La Jolla Institute for Immunology (LJI) bring together research findings from COVID-19 researchers around the world. The results are striking: human T cells can target more than 1,400 sites on the SARS-CoV-2 virus. Our lab and many others have shown this very broad and diverse T cell response, says LJI Research Assistant Professor Daniela Weiskopf, Ph.D., co-author of the
Cell Host & Microbe review.
This kind of research review, called a meta-analysis, pools the results of multiple studies, and the researchers give close consideration to how the studies were conducted.
In the case of COVID-19, a global meta-analysis of T cell response studies is especially helpful because different patient populations can have vastly different immune responses, based on their genetic differences and past disease history.